June 28, 2013 / 12:51 PM / 7 years ago

Bayer says FDA requests more data on Xarelto for stent patients

FRANKFURT, June 28 (Reuters) - Bayer said the U.S. Food and Drug Administration has put on hold a decision over the use of anti-clotting pill Xarelto to prevent stent thrombosis in patients suffering from acute coronary syndrome, requesting more information.

Bayer said on Friday it was confident that together with development partner Johnson & Johnson it can address the questions in the FDA’s so-called “complete response letter”.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below